Diclofenac hydroxyethylpyrrolidine clinical trials
Also written diclofenac epolamine.
How each study uses diclofenac hydroxyethylpyrrolidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 31 Jan 2007 · FLECTOR · NDA 021234 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2014 (2)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 2 |
| 2017 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
IBSA Institut Biochimique SA (2) · Fidia Farmaceutici s.p.a. (1) · Actavis Inc. (1) · Specialized Arab Hospital (1) · Western Galilee Hospital-Nahariya (1)
Often tested with
Tested in the same studies.
Diclofenac (1) · Orphenadrine (1) · Tramadol (1) · Dipyrone (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses diclofenac hydroxyethylpyrrolidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue InjuryCompletedPhase 3IBSA Institut Biochimique SANCT05171673Written as Licart™ (diclofenac epolamine) topical systemHow we know
- Comparative Bioavailability and Local Tolerability of Two Topical Diclofenac Plasters Applied Once and Twice a DayCompletedPhase 1Fidia Farmaceutici s.p.a.NCT04585321Written as Flector® topical plaster containing 180 mg of diclofenac hydroxyethylpyrrolidine equivalent to 140 mg of sodium diclofenacHow we know
- Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle SprainCompletedPhase 3Actavis Inc.NCT02324270Written as Diclofenac epolamineHow we know
- Patient Preferences, Analgesic Delivery Method and Pain Reduction in Spine PatientsWithdrawnNot applicableWestern Galilee Hospital-NahariyaNCT01263652Written as Diclofenac hydroxyethylpyrrolidineHow we know
- Safety Study of Flector Patch in Children With Minor Soft Tissue InjuriesCompletedPhase 4IBSA Institut Biochimique SANCT02132247Written as Diclofenac hydroxyethylpyrrolidineHow we know
- Diclofenac vs. Placebo in a Randomized Double Blind Controlled Trial in Post ERCP PancreatitisCompletedPhase 1Specialized Arab HospitalNCT01946984Written as Diclofenac hydroxyethylpyrrolidineHow we know
As the comparator · 2 — what is tested is compared with diclofenac hydroxyethylpyrrolidine
- Clinical Trial With Diclofenac Sodium Medicated Plaster in Patients With Impact Injuries of the LimbsCompletedPhase 3Fidia Farmaceutici s.p.a.NCT04976088Written as Diclofenac epolamine (DIEP) 180mg medicated plaster, FlectorHow we know
- Efficacy of PENNSAID® for Pain Management in the Emergency DepartmentWithdrawnNot applicableUniversity of UtahNCT01350622Written as Diclofenac hydroxyethylpyrrolidineHow we know
Codes
What other systems call diclofenac hydroxyethylpyrrolidine · ClinicalTrials.gg INT003510
- MeSH (NLM) C064142diclofenac hydroxyethylpyrrolidineOne source ClinicalTrials.gov
- RxNorm 40968One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C064142 | diclofenac hydroxyethylpyrrolidine | One source ClinicalTrials.gov |
| RxNorm | 40968 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.